Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
Hepatocellular carcinoma (HCC) is one of the most common malignant disease worldwide with an
increasing incidence in industrialized countries. For patients with advanced HCC no efficient
treatment is currently available. The objective of this study is to assess the efficacy and
safety of octreotide in patients with advanced hepatocellular carcinoma.